HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vanderbilt licenses mGluR4 modulators for Parkinson’s to BMS

Executive Summary

Vanderbilt University’s Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has licensed Bristol-Myers Squibb Co. rights to develop and market its positive allosteric modulators of the metabotropic glutamate receptor 4 (mGluR4) for Parkinson’s disease (PD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies